Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...3132333435363738394041...123124»
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering. (Pubmed Central) -  May 22, 2023   
    Subsequent clinical trials have identified multiple tyrosine kinase inhibitors, such as Lenvatinib, Cabozantinib, and Regorafenib, for the treatment of hepatocellular carcinoma, with survival benefits for the patient...In this review, we summarize current approaches to targeted therapy for HCC patients and the establishment of several patient-derived preclinical models of hepatocellular carcinoma. We also discuss the challenges and opportunities of targeted therapy for hepatocellular carcinoma and how to achieve personalized treatment with the continuous development of targeted therapies and bioengineering technologies.
  • ||||||||||  Journal, Metastases:  An update on: safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma. (Pubmed Central) -  May 22, 2023   
    The aim of this review is to compare the different safety profiles of first-line immune-based combinations versus sunitinib across the four respective pivotal trials (CheckMate 214, CheckMate 9ER, KEYNOTE-426, and CLEAR), with a particular attention to patients' health-related quality of life (HRQoL) assessment...The specific patterns of toxicities of the approved first-line immune-based combinations, along with the impact of these interventions on patients' HRQoL, demand a deeper consideration by physicians while choosing the appropriate treatment for each individual mRCC patient. Both safety profile and HRQoL evaluation could be exploited to guide first-line treatment selection in this setting.
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) -  May 22, 2023   
    P1,  N=2, Active, not recruiting, 
    High serum OPN levels were associated with poor response to Atez/Bev in patients with uHCC. Recruiting --> Active, not recruiting | N=40 --> 2 | Trial completion date: Feb 2026 --> Jun 2027 | Trial primary completion date: Feb 2023 --> Jun 2025
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Biomarker, Journal, PD(L)-1 Biomarker:  Tumor?infiltrating CD8 T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma. (Pubmed Central) -  May 19, 2023   
    There were no differences in response rate or progression-free survival between these groups. Although the present study included only a limited number of patients, the findings suggested that CD8 TILs could be a biomarker for predicting response to systemic chemotherapy in HCC.
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) -  May 16, 2023   
    P1,  N=20, Recruiting, 
    These findings suggest that high numbers of PD-L1-expressing cells within tumor tissue prior to MKI treatment can serve as a biomarker to predict favorable PFS in HCC patients. Not yet recruiting --> Recruiting | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  MODULE 6: Future Directions in the Management of Metastatic NSCLC (Hilton Chicago, Grand Ballroom ) -  May 15, 2023 - Abstract #ASCO2023ASCO_7042;    
    This event is organized and accredited by Research to Practice and supported through educational grants provided by AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Novocure Inc, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc. Biologic rationale for targeting TROP2 in lung cancer; mechanism of action of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (dato-DXd) Clinical activity observed with dato-DXd as monotherapy and in combination with other systemic anticancer therapies for advanced NSCLC; ongoing Phase III studies Incidence and severity of toxicities associated with dato-DXd, including interstitial lung disease Mechanism of action of tumor treating fields; preclinical and early clinical data supporting the investigation of this treatment modality in NSCLC Emerging positive results from the Phase III LUNAR study of tumor treating fields concurrent with immune checkpoint inhibition or docetaxel for metastatic NSCLC after failure of platinum-based therapy Potential clinical role of tumor treating fields in the care of patients with progressive NSCLC Early-phase data with anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, ramucirumab/pembrolizumab, lenvatinib/pembrolizumab, sitravatinib/nivolumab, durvalumab/ceralasertib) for progressive advanced NSCLC Other promising novel agents and strategies in clinical development for advanced NSCLC
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Metastases:  Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors. (Pubmed Central) -  May 14, 2023   
    Biologic rationale for targeting TROP2 in lung cancer; mechanism of action of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (dato-DXd) Clinical activity observed with dato-DXd as monotherapy and in combination with other systemic anticancer therapies for advanced NSCLC; ongoing Phase III studies Incidence and severity of toxicities associated with dato-DXd, including interstitial lung disease Mechanism of action of tumor treating fields; preclinical and early clinical data supporting the investigation of this treatment modality in NSCLC Emerging positive results from the Phase III LUNAR study of tumor treating fields concurrent with immune checkpoint inhibition or docetaxel for metastatic NSCLC after failure of platinum-based therapy Potential clinical role of tumor treating fields in the care of patients with progressive NSCLC Early-phase data with anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, ramucirumab/pembrolizumab, lenvatinib/pembrolizumab, sitravatinib/nivolumab, durvalumab/ceralasertib) for progressive advanced NSCLC Other promising novel agents and strategies in clinical development for advanced NSCLC No abstract available
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma (clinicaltrials.gov) -  May 12, 2023   
    P1,  N=30, Recruiting, 
    Effective, durable management of ATC will rely on an understanding not only of genetics but also on the role of the tumor microenvironment. Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Concomitant Metastatic Hurthle Cell Carcinoma and Rectal Cancer, Challenges in Diagnosis and Management (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2565;    
    He underwent 6 cycles of palliative chemotherapy with carboplatin and Taxol for carcinoma of unknown origin...He received suppressive dose levothyroxine...For rectal cancer, he received radiation therapy and capecitabine.Our case is interesting for several reasons...Combination therapy with Lenvatinib and Pembrolizumab is currently under trial for aggressive thyroid malignancy. It will be interesting to follow the clinical outcomes in this individual.
  • ||||||||||  Real World Use of Systemic Therapy for Treatment of Advanced Thyroid Cancer (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_1664;    
    We identified patients with thyroid cancer who had prescription claims for at least one of the 15 SMKIs of interest (axitinib, cabozantinib, dabrafenib, entrectinib, everolimus, larotrectinib, lenvatinib, pazopanib, pralsetinib, selpercatinib, sorafenib, sunitinib, trametinib, vandetanib, and vemurafenib)...Since 2015 when lenvatinib was approved by the FDA for treatment of advanced differentiated thyroid cancer, it has become the most commonly prescribed SMKI for treatment of advanced thyroid cancer. However, variation exists in which SMKIs are used to treat patients with advanced thyroid cancer, with almost one-quarter of patients initiated on commercially available SMKIs.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Anti-angiogenic multi-kinase inhibitor in NUTM1 rearranged carcinoma of Thyroid (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_291;    
    Importantly, NUT1 stain could be negative and NGS is the gold standard for accurate diagnosis. Although our study is limited by one case report, we hope that by highlighting the spectrum of this disease that more cases will be recognized, facilitating risk stratification and improved treatment, and further enabling future studies to explore the clinical management and biology of NUTM1 rearranged carcinoma of thyroid.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  Lenvatinib resistance mechanism and potential ways to conquer. (Pubmed Central) -  May 8, 2023   
    The latest literature review of LVN caused resistance would bring some ways for further study of LVN. We call for more attention to the pharmacological parameters of LVN in clinic, which was rarely and would supply key elements for drug itself in human beings and help to find the resistance target or idea for further study.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib plus checkpoint inhibitors (ICIs) versus sorafenib plus ICIs as first-line treatment for unresectable hepatocellular carcinoma with Child-Pugh B (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_579;    
    HRQoL data from Study 309/KEYNOTE-775, with previously published efficacy and safety results, indicate that LEN+PEMBRO has an overall favourable benefit/risk profile versus TPC for the treatment of patients with aEC. The regimen of Lenvatinib plus ICIs had improved ORR compared to the regimen of sorafenib plus ICIs for uHCC with Child-Pugh B. After treating with sorafenib plus ICIs or Lenvatinib plus ICIs, the prognosis of patients with uHCC was similar between the subgroup of those with Child-Pugh B7 and those with Child-Pugh B8/9.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Low dose nivolumab with TKI in advanced HCC: Real world outcomes from India (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_566;    
    Outcomes are improved as compared to historic cohort of first-line TKI alone in this disease with poor prognosis. Only a quarter of patients in the real world receive subsequent lines of treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments (POSTER HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_231;    
    Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
    Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases:  Lenvatinib with Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer (clinicaltrials.gov) -  May 3, 2023   
    P2,  N=90, Recruiting, 
    Antibodies against PD-1/PD-L1 can enhance the efficacy of lenvatinib in the management of hepatocellular carcinoma. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Journal, Adverse events, PD(L)-1 Biomarker, Metastases:  The efficacy and adverse effects of nivolumab and lenvatinib in the treatment of advanced hepatocellular carcinoma. (Pubmed Central) -  May 2, 2023   
    All in all, nivolumab combined with lenvatinib for advanced hepatocellular carcinoma can improve tumor control, reduce tumor load, and improve liver function and immune function. Common adverse reactions include fatigue, loss of appetite, elevated blood pressure, hand-foot skin reaction, diarrhea, and rash, which should be controlled during treatment.